Re: Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer

Gerben R Borst; Jose Belderbos; Sjaak Burgers; Jan-Jakob Sonke; Joos Lebesque

doi:10.1016/j.radonc.2009.02.002

Re: Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer

Gerben R Borst, Jose Belderbos, Sjaak Burgers, Jan-Jakob Sonke, Joos Lebesque

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	461; author reply 461-2
Journal	Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Volume	91
Issue number	3
DOIs	https://doi.org/10.1016/j.radonc.2009.02.002
Publication status	Published - Jun 2009

Keywords

Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Carboplatin/administration & dosage
Carcinoma, Non-Small-Cell Lung/drug therapy
Cisplatin/administration & dosage
Combined Modality Therapy
Deoxycytidine/administration & dosage
Dyspnea/etiology
Female
Humans
Lung/radiation effects
Lung Neoplasms/drug therapy
Male
Middle Aged
Radiotherapy Dosage
Treatment Outcome
Vinblastine/administration & dosage
Vinorelbine

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.radonc.2009.02.002

Cite this

@article{8db689c0b0fa4b9e8153bc3152b48a4d,

title = "Re: Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer",

keywords = "Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Carboplatin/administration & dosage, Carcinoma, Non-Small-Cell Lung/drug therapy, Cisplatin/administration & dosage, Combined Modality Therapy, Deoxycytidine/administration & dosage, Dyspnea/etiology, Female, Humans, Lung/radiation effects, Lung Neoplasms/drug therapy, Male, Middle Aged, Radiotherapy Dosage, Treatment Outcome, Vinblastine/administration & dosage, Vinorelbine",

author = "Borst, {Gerben R} and Jose Belderbos and Sjaak Burgers and Jan-Jakob Sonke and Joos Lebesque",

year = "2009",

month = jun,

doi = "10.1016/j.radonc.2009.02.002",

language = "English",

volume = "91",

pages = "461; author reply 461--2",

journal = "Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology",

issn = "0167-8140",

publisher = "Elsevier BV",

number = "3",

}

Re: Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer. / Borst, Gerben R; Belderbos, Jose; Burgers, Sjaak et al.
In: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, Vol. 91, No. 3, 06.2009, p. 461; author reply 461-2.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Re

T2 - Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer

AU - Borst, Gerben R

AU - Belderbos, Jose

AU - Burgers, Sjaak

AU - Sonke, Jan-Jakob

AU - Lebesque, Joos

PY - 2009/6

Y1 - 2009/6

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Carboplatin/administration & dosage

KW - Carcinoma, Non-Small-Cell Lung/drug therapy

KW - Cisplatin/administration & dosage

KW - Combined Modality Therapy

KW - Deoxycytidine/administration & dosage

KW - Dyspnea/etiology

KW - Female

KW - Humans

KW - Lung/radiation effects

KW - Lung Neoplasms/drug therapy

KW - Male

KW - Middle Aged

KW - Radiotherapy Dosage

KW - Treatment Outcome

KW - Vinblastine/administration & dosage

KW - Vinorelbine

U2 - 10.1016/j.radonc.2009.02.002

DO - 10.1016/j.radonc.2009.02.002

M3 - Article

C2 - 19243847

SN - 0167-8140

VL - 91

SP - 461; author reply 461-2

JO - Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

JF - Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

IS - 3

ER -